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Honokiol, a constituent of Magnolia species, inhibits 
adrenergic contraction of human prostate strips and 
induces stromal cell death
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Christian Gratzke, Martin Hennenberg
Department of Urology, Ludwig-Maximilians University, Munich, Germany
Purpose: Smooth muscle contraction and prostate growth are important targets for medical therapy of lower urinary tract 
symptoms (LUTS) in patients with benign prostatic hyperplasia. Honokiol and Magnolol are lignan constituents of Magnolia species, 
which are used in traditional Asian medicine. Here, we examined effects of honokiol and magnolol on contraction of human prostate 
tissue and on growth of stromal cells. 
Methods: Prostate tissues were obtained from radical prostatectomy. Contraction of prostate strips was examined in organ bath 
studies. Effects in stromal cells were assessed in cultured immortalized human prostate stromal cells (WPMY-1). Ki-67 mRNA was 
assessed by reverse transcription-polymerase chain reaction, and proliferation by a fluorescence 5-ethynyl-2’-deoxyuridine assay. 
Results: Honokiol (100 μM) reduced noradrenaline-induced contractions, which was significant at 10- to 100-µM noradrenaline. 
Honokiol reduced phenylephrine-induced contractions, which was significant at 3- to 100-µM phenylephrine. Honokiol reduced 
electric field stimulation-induced contractions very slightly. In WPMY-1 cells, honokiol (24 hours) induced cell death. Magnolol (100 
µM) was without effects on contraction, and cellular viability. 
Conclusions: Honokiol inhibits smooth muscle contraction in the human prostate, and induces cell death in cultured stromal cells. 
Because prostate smooth muscle tone and prostate growth may cause LUTS, it appears possible that honokiol improves voiding 
symptoms.
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INTRODUCTION
Medical therapies of lower urinary tract symptoms (LUTS) tar-
get either smooth muscle contraction in the lower urinary tract, 
or prostate growth [1]. In fact, exaggerated α1-adrenoceptor-
mediated contraction, and enlargement of the prostate may both 
contribute to bladder outlet obstruction and LUTS in patients 
with benign prostatic hyperplasia (BPH) [2]. Consequently, op-
tions for medical treatment comprise application of α1-blockers 
to induce prostate smooth muscle relaxation, and 5α-reductase 
inhibitors to reduce prostate growth and volume [1]. 
 In addition to α1-blockers and 5α-reductase inhibitors, the 
use of phytotherapeutics is extremely widespread at least in 
Western Europe and the United States [3,4]. Several prepara-
tions containing combined plant extracts are available without 
prescription, and still represent an important mainstay of LUTS 
therapy [5]. Their use is widespread; it has been estimated that 
phytotherapeutics may still reach up to 30 % of total expenses 
for medical LUTS therapy, which amounted to 4.8 billion USD 
worldwide in 2009 [3,6,7]. Although their effects are controver-
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the equilibration period, spontaneous decreases in tone are 
usually observed. Therefore, tension was adjusted three times 
during the equilibration period, until a stable resting tone 
(0.5 g) was attained. After the equilibration period, maximum 
contraction induced by 80mM KCl (Krebs-Henseleit solution 
where NaCl was exchanged by KCl) was assessed. Subsequent-
ly, chambers were washed three times with Krebs-Henseleit 
solution for a total of 30 minutes. Cumulative concentraction 
response curves for noradrenaline or phenylephrine (both 
from Sigma-Aldrich, Munich, Germany) were created after ad-
dition of 100-µM honokiol, 100-µM magnolol (both from Santa 
Cruz Biotechnology Inc., Santa Cruz, CA, USA), or an equiva-
lent volume of solvent (dimethylsulfoxide, DMSO). Fequency 
response curves induced by electric field stimulation (EFS) 
were created before and after addition of inhibitors or solvent 
(DMSO for honokiol, water for tamsulosin, and DMSO for the 
combination of both). Inibitors or DMSO were applied 45 min-
utes before concentration or frequency response curves. 
3. Cell culture
WPMY-1 cells are an immortalized cell line obtained from 
nonmalignant human prostate stroma. Cells were obtained 
from American Type Culture Collection (Manassas, VA, USA), 
and kept in Rosewell Park Memorial Institute 1640 (Gibco, 
Carlsbad, CA, USA) supplemented with 10% fetal calf serum 
(FCS) and 1% penicillin/streptomycin at 37°C with 5% CO2. 
Before stimulation with honokiol (100 µM, 24 hours) or mag-
nolol (100 µM, 24 hours), the medium was changed to a FCS-
free medium. At the end of the experiment, cells were micro-
scoped and pictures were taken using the AxioCam (Zeiss, 
Oberkochen, Germany). 
4. Determination of mRNA expression by real-time 
polymerase chain reaction
Total RNA was isolated from WPMY-1 cells using the RNeasy 
mini Kit (Qiagen, Hilden, Germany). After reverse transcrip-
tion with AMV reverse transcriptase (Promega, Fitchburg, WI, 
USA), real-time reverse transcription-polymerase chain reac-
tion was performed to assess Ki-67 and ß-actin expression 
with QuantiTect Primer Assays (Qiagen) using a LightCycler 
Instrument (Roche Diagnostics, Rotkreuz, Switzerland).
5. Cell proliferation assay
WPMY-1 cells were plated with a density of 50,000/well on a 
16-well chambered coverslip (Thermo Scientific, Waltham, 
MA, USA). After 24 hours, cells were treated with honokiol 
(100µM) or magnolol (100µM) in FCS-free medium. After 
further 24 hours, the medium was changed to a 10mM 5-ethy-
sially discussed, several clinical studies meeting World Health 
Organization (WHO) criteria demonstrated improvements of 
LUTS, urinary flow rate, and postvoid residual volume [5]. 
 Honokiol and magnolol are neolignan compounds of dif-
ferent Magnolia species [8]. Bark and flowers from Magnolia 
obovata and Magnolia officinalis have been used to date in 
traditional Chinese and Japanese herbal medicine for treat-
ment of gastrointestinal disorders, anxiety, and allergic dis-
ease [8]. Following isolation and identification of honokiol 
and magnolol from magnolia extracts, their antitumor activity 
has been recognized and examined in experimental models 
[8]. Recent studies suggested that they may induce smooth 
muscle relaxation in the cardiovascular system, airways, and 
gastrointestinal tract [9-16]. However, their actions in the 
lower urinary tract are unknown to date. Here, we investigated 
the effects of honokiol and magnolol on contraction of human 
prostate tissue.
MATERIALS AND METHODS
1. Human prostate tissue
Human prostate tissues were obtained from April 2013 to Sep-
tember 2013 from patients undergoing radical prostatectomy 
(n=38) for prostate cancer, but without previous transurethral 
resection of the prostate (TURP). The research was carried out 
in accordance with the Declaration of Helsinki of the World 
Medical Association, and has been approved by the ethics 
committee of the Ludwig-Maximilians University, Munich, 
Germany. Approval did not allow acquisition or storage of any 
patients’ data, so that all samples were treated anonymously. 
Consequently, data analysis with relation to patients’ charac-
teristics (e.g., age) was not possible, what may be viewed as a 
limitation of the study. Tissues in our study were exclusively 
taken from the periurethral zone. Most prostate tumors are 
located to the peripheral zone. Consequently, the extent of 
malignant areas (if any) in our samples may be neglected. Tis-
sue samples did not exhibit macroscopical signs of neoplasia, 
cancer, or inflammation. Samples were immediately taken 
after prostatectomy and subsequent macroscopical patho-
logical examination. Organ bath studies were performed im-
mediately after sampling. 
2. Tension measurements
Prostate strips (6 mm ×3 mm ×3 mm) were mounted in 10 
mL aerated (95% O2 and 5% CO2) tissue baths (Föhr Medical 
Instruments, Seeheim, Germany), containing Krebs-Henseleit 
solution (37°C, pH 7.4). Preparations were stretched to 0.5 g 
and left to equilibrate for 45 minutes. In the initial phase of 
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α1-adrenoceptor. Aqueous stock solutions of phenylephrine 
and noradrenaline (10mM) were freshly prepared before 
each experiment.
7. Statistical analysis
Data are presented as mean±standard error of the mean (SEM) 
with the indicated number of experiments. Two-tailed Student 
t-test was used for paired or unpaired observations. Values of 
P <0.05 were considered statistically significant. Concentra-
tions producing the half-maximal responses (EC50 values) for 
contractile agonists were calculated using GraphPad Prism ver. 
6 (GraphPad Software Inc., La Jolla, CA, USA).
RESULTS
1. Adrenergic contraction
Noradrenaline and the α1-adrenergic agonist phenylephrine 
induced concentration-dependent contractions of human 
nyl-2’-deoxyuridine (EdU) solution in FCS-free medium con-
taining honokiol or magnolol. After 20 hours, cells were fixed 
with 3.7% formaldehyde. EdU incorporation was determined 
using the “EdU-Click 555” cell proliferation assay (Baseclick, 
Tutzing, Germany) according to the manufacturer’s instruc-
tions. In this assay, incorporation of EdU into DNA is assessed 
by detection with fluorescing 5-carboxytetramethylrhoda-
mine. Counterstaining of all nuclei was performed with 4’,6-di-
amidino-2-phenylindole. Cells were analyzed by flourescence 
microscopy (excitation, 546 nm; emission, 479 nm).
6. Drugs and solutions
Honokiol (2-(4-hydroxy-3-prop-2-enyl-phenyl)-4-prop-2-
enyl-phenol) and magnolol (4-Allyl-2-(5-allyl-2-hydroxy-
phenyl)phenol) are biphenyl lignans, isolated from Magnolia 
species extracts. Stock solutions (10mM) were prepared with 
DMSO, and kept at –20°C until use. Phenylephrine ((R)-3-[-
1-hydroxy-2-(methylamino)ethyl]phenol) is an agonist of the 
Fig. 1. Effects of honokiol (A) and magnolol (B) on noradrenaline- and phenylephrine-induced contractions of human prostate strips. 
Contractions were assessed after application of solvent (dimethylsulfoxide, DMSO), and honokiol (100µM) or magnolol (100µM). Ten-
sions are expressed as % of contraction induced by 80mM KCl. Data are mean±standard error of the mean from experiments with 
prostates from n=10 patients for noradrenaline/honokiol, n=8 patients for phenylephrine/honokiol, n=6 patients for noradrenaline/
magnolol, or n=5 patients for phenylephrine/magnolol. *P<0.05 for DMSO vs. honokiol.
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prostate strips (Fig. 1). These were reduced by honokiol (100 
µM). Significant inhibition of noradrenaline-induced contrac-
tion by honokiol was observed at 10µM (P=0.016 for honokiol 
vs. DMSO), 30µM (P=0.034), and 100µM (P=0.035) noradren-
aline (Fig. 1A). Significant inhibition of phenylephrine-induced 
contraction by honokiol was observed at 3µM (P =0.013), 
10µM (P =0.0049), 30µM (P =0.0028), and 100µM (P =0.015) 
phenylephrine (Fig. 1A). In addition to inhibition of force gen-
eration, honokiol significantly increased the EC50 values for 
noradrenaline (P=0.022 for honokiol vs. DMSO) and phenyl-
ephrine (P=0.025) (Table 1). 
 In contrast, application of magnolol (100µM) caused 
only slight inhibition of noradrenaline- and phenylephrine-
induced contractions, without being significant (Fig. 1B). EC50 
values for noradrenaline or phenylephrine was not changed 
by magnolol (Table 1).
2. EFS-induced contraction
EFS induced frequency-dependent contractions of human 
prostate strips (Fig. 2). Contractions were virtually identical 
before and after application of DMSO (Fig. 2). In contrast, 
contractions induced by 8, 16, and 32 were slightly reduced af-
ter application of honokiol, without being significant (Fig. 2). 
3. Effects of honokiol on WPMY-1 cells
Application of honokiol (100µM) for 24 hours induced death 
of cultured WPMY-1 cells (Fig. 3). Microscopic examination 
revealed that cells were completely destroyed by treatment 
with honokiol.
4. Effects of magnolol on WPMY-1 cells
Application of magnolol (100µM) for 24 hours was without ef-
fect on cell cycle of WPMY-1 cells. In a fluorescent EdU assay, 
53% of cells showed proliferation after application of magno-
lol, while 57% showed proliferation in control samples (Fig. 4). 
Magnolol did not change the mRNA expression of the prolif-
eration marker, Ki-67 (Fig. 4).
DISCUSSION
Our findings demonstrate that honokiol may interfer with 
contraction and cell cycle in the human prostate. Induction of 
smooth muscle relaxation by α1-adrenoceptor blockers, and 
inhibition of prostate growth by 5α-reductase inhibitors are 
important strategies for medical LUTS therapy [17]. However, 
a single substance targeting prostate contraction and growth 
at once has not been approved to date. Currently, combina-
tion therapies including α1-blockers and 5α-reductase inhibi-
Fig. 2. Effects of honokiol (100µM) on electric field stimulation-induced contractions of human prostate strips. Contractions were 
compared before and after application of solvent (dimethylsulfoxide, DMSO) (A) or honokiol (B) to prostate strips. Tensions are ex-
pressed as % of contraction induced by 80mM KCl. Data are mean±standard error of the mean from experiments with prostates from 
n=9 patients.
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Fig. 3. Effect of honokiol on WPMY-1 cells. Honokiol (100µM) 
was applied to cultured WPMY-1 cells for 24 hours. Shown are 
representative pictures after application of honokiol or from 
control samples without honokiol, from a series of 3 indepen-
dent experiments with identical results.
Control Honokiol
Table 1. EC50 values for noradrenaline- and phenylephrine-in-
duced contractions of human prostate strips, after application 
of honokiol, magnolol, or solvent (DMSO)
 
LogEC50 
noradrenaline (M)
LogEC50 
phenylephrine (M)
Honokiol
   DMSO
   Honokiol
  n=10
–5.205±0.049
–4.926±0.097a)
n=8
–5.159±0.099
–4.622±0.19a)
Magnolol
   DMSO
   Magnolol
n=6
–5.217±0.186
–5.18±0.155
n=5
–5.2±0.139
–5.13±0.067
Values are presented as mean±standard error of the mean. 
DMSO, dimethylsulfoxide.
a)P<0.03 vs. corresponding DMSO control.
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tors are applied to patients, where monotherapy with α1-
blockers is insufficient [17]. However, these combinations 
do not only provide increased benefits, but also additive side 
effects [17]. Therefore, a single substance addressing both 
components at once together with low side effects may be ap-
preciated. Numerous studies described inhibition of different 
smooth muscle preparations and inhibition of cellular growth 
and proliferation by honokiol and magnolol. This prompted 
us to investigate effects of honokiol and magonolol on pros-
tate smooth muscle contraction, and growth of stromal cells.
 In our tension measurements, honokiol caused significant 
inhibition of phenylephrine- and noradrenaline-induced 
contractions, and increased EC50 values for both agonists. In 
the human prostate, α1-adrenoceptor-mediated contraction 
critically determines smooth muscle tone [2]. A minor effect 
of honokiol was observed at EFS-induced contractions with 
high frequencies. Inhibition of smooth muscle contraction by 
honokiol has been previously reported from the guinea pig 
ileum, porcine trachea, rat uterus, and from rat aortic rings 
[9-12]. To the best of our knowledge, our study using human 
prostate tissue is the first showing inhibition of smooth mus-
cle contraction by honokiol in a smooth muscle preparation 
of human origin.
 In WPMY-1 cells, a line of stromal cells obtained from a 
nonmalignant human prostate, application of honokiol in-
duced cell death. This is in line with previous findings, where 
honokiol was studied in prostate cancer or smooth muscle 
cells [18-22]. Thus, honokiol induced apoptosis or cell cycle 
arrest in different lines of prostate cancer cells [19,20,22]. 
Similarly, it induced apoptosis and cell cycle arrest in cul-
tured vascular smooth muscle cells [18,21]. Proliferation of 
stromal cells is critical for prostate growth and enlargement 
in BPH [23]. Together, this suggests that in vivo application of 
honokiol may reduce growth and volume of the hyperplastic 
prostate.
 Contrary to previous findings from other organs and spe-
cies, magnolol caused no significant inhibition of smooth 
muscle contractions in human prostate strips. Inhibition of 
smooth muscle contraction by magnolol was reported from 
preparations of rat and guinea pig colon, guinea pig ileum, 
rat aortic rings, rat uterus, and porcine trachea [9-11,13-16]. 
Similarly, magnolol was without effect on cell cycle of WPMY-
1 cells, although it induces apoptosis or cell cycle arrest in 
cultured prostate cancer and smooth muscle cells [24-28]. 
Based on studies in the cardiovascular system, it has been 
previously assumed that effects of magnolol may be cell type- 
and dosage-specific [29]. Obviously, limitations of magnolol 
actions are not confined to the cardiovascular system, but 
also occur in the lower urinary tract, where magnolol acts on 
smooth muscle contraction in the rat uterus but not in the 
human prostate [11].
 The dual actions of honokiol on contraction and cell cycle 
in the prostate appears attractive for therapy of LUTS sugges-
tive of benign prostatic obstruction (BPO). Whether honokiol 
induces improvement of voiding symptoms can only be as-
sessed in vivo. Because prostate-dependent mechanisms can 
not be studied in wide-spread rodent models, urodynamic 
effects of honokiol should preferentially examined in clinical 
proof-of-concept studies. To the best of knowledge, tests in 
preclinical models did not provide any clues, which may ex-
clude studies with oral uptake of honokiol. In previous stud-
ies, which adressed antitumor activity and pharmacokinetics 
in different animal models, honokiol-containing preparations 
were mostly applied intravenously, but also orally or even 
rectally in rats [30]. After rectal application, plasma concen-
B
Fig. 4. Effects of magnolol on cell cycle of WPMY-1 cells. Magno-
lol (100µM) was applied to cultured WPMY-1 cells for 24 hours. 
(A) Proliferation was assessed by a 5-ethynyl-2’-deoxyuridine as-
say, where red-orange fluorescence of 5-carboxytetramethyl-
rhodamine (5-TAMRA) in nuclei indicates proliferation. Counter-
staining of all nuclei was performed with 4’,6-diamidino-2-phe-
nylindole (DAPI). (B) mRNA expression of the proliferation mark-
er, Ki-67, and of β-actin was assessed by quantitative reverse 
transcription-polymerase chain reaction. Content in magnolol 
samples was referred to control samples, which were set to 1. 
Shown are representative pictures (A) or mean±standard error of 
the mean (B) from series with 3 independent experiments.
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trations of honokiol may be up to six times higher compared 
to oral application, what may be interesting for applications 
in LUTS therapy [30]. Meanwhile, liposomal formulations of 
honokiol including polyethylene glycol coated (PEGylated) 
liposomal honokiol have been and are still developed and 
tested for in vivo applicatons for anticancer therapies [30-32]. 
Toxicologic and mutagenic studies in preclinical models sug-
gested that honokiol may be safe and is not genotoxic [30].
 For treatment of LUTS, different preparations containing 
single or mixed plant extracts are available [1,5]. Their high 
popularity may raise from their easy availability, but also from 
disappointment of established clinical options. It has been 
estimated that 36%-45% of patients are not satisfied from 
treatment with α1-blockers or 5α-reductase inhibitors, raising 
the need for ablative treatments [17]. Symptoms, assessed as 
“International Prostate Symptom Score” (IPSS) are improved 
to 30%–50% by α1-blockers and to 15%–30% by 5α-reductase 
inhibitors, but to 10%–34% by placebos [1,2,6]. Similarly, maxi-
mal flow rate (Qmax) is increased to 15%–40% by α1-blockers, 
while increases up to 27% were observed in response to pla-
cebo [1,2,6]. Finally, side effects may account for discontinu-
ation of medical therapy, with varying rates for α1-blockers or 
5α-reductase inhibitors [6]. Together, this raises a high interest 
for alternative options.
 LUTS treatment with plant extracts is still controversially 
discussed. Several clinical studies meeting international WHO-
BPH standards addressed effects of phytotherapy in patients 
with LUTS suggestive of BPO, with adverse results. Prepara-
tions containing plant extracts were often indistinguishable 
from placebos, with few exceptions [33-37]. Positive findings 
mostly concerned IPSS, while improvements of Qmax were 
found rarely [35,36]. Based on these findings, neither a recom-
mendation, nor a clear rejection/dismissial of phytotherapies 
was given [1,5].
 In conclusion, Honokiol inhibits smooth muscle contrac-
tion in the human prostate, and induces cell death in cultured 
stromal cells. Because prostate smooth muscle tone and 
prostate growth may cause LUTS, it appears possible that ho-
nokiol may improve voiding symptoms in patients with BPH.
CONFLICT OF INTEREST
No potential conflict of interest relevant to this article was re-
ported.
ACKNOWLEDGMENTS
We thank Prof. Dr. E. Noessner and her coworkers for support 
with fluorescence microscopy. This study was supported by 
grants from the “Deutsche Forschungsgemeinschaft” (DFG) 
(grants HE 5825/2-1 and GR 3333/2-1), and from the “Fried-
rich-Baur-Stiftung” (grant 73/13).
 
REFERENCES
1. Oelke M, Bachmann A, Descazeaud A, Emberton M, Gra-
vas S, Michel MC, et al. EAU guidelines on the treatment 
and follow-up of non-neurogenic male lower urinary tract 
symptoms including benign prostatic obstruction. Eur Urol 
2013;64:118-40.
2. Hennenberg M, Stief CG, Gratzke C. Prostatic α1-adrenoceptors: 
New concepts of function, regulation, and intracellular signal-
ing. Neurourol Urodyn 2014;33:1074-85.
3. Lukacs B, Cornu JN, Aout M, Tessier N, Hodee C, Haab F, et 
al. Management of lower urinary tract symptoms related to 
benign prostatic hyperplasia in real-life practice in france: a 
comprehensive population study. Eur Urol 2013;64:493-501.
4. MacDonald R, Tacklind JW, Rutks I, Wilt TJ. Serenoa repens 
monotherapy for benign prostatic hyperplasia (BPH): an up-
dated Cochrane systematic review. BJU Int 2012;109:1756-61.
5. Madersbacher S, Berger I, Ponholzer A, Marszalek M. Plant 
extracts: sense or nonsense? Curr Opin Urol 2008;18:16-20.
6. Madersbacher S, Marszalek M, Lackner J, Berger P, Schatzl G. 
The long-term outcome of medical therapy for BPH. Eur Urol 
2007;51:1522-33.
7. Ventura S, Oliver Vl, White CW, Xie JH, Haynes JM, Exintaris 
B. Novel drug targets for the pharmacotherapy of benign pros-
tatic hyperplasia (BPH). Br J Pharmacol 2011;163:891-907.
8. Lee YJ, Lee YM, Lee CK, Jung JK, Han SB, Hong JT. Therapeu-
tic applications of compounds in the Magnolia family. Phar-
macol Ther 2011;130:157-76.
9. Chan SS, Zhao M, Lao L, Fong HH, Che CT. Magnolol and ho-
nokiol account for the anti-spasmodic effect of Magnolia offici-
nalis in isolated guinea pig ileum. Planta Med 2008;74:381-4.
10. Ko CH, Chen HH, Lin YR, Chan MH. Inhibition of smooth mus-
cle contraction by magnolol and honokiol in porcine trachea. 
Planta Med 2003;69:532-6.
11. Lu YC, Chen HH, Ko CH, Lin YR, Chan MH. The mechanism of 
honokiol-induced and magnolol-induced inhibition on mus-
cle contraction and Ca2+ mobilization in rat uterus. Naunyn 
Schmiedebergs Arch Pharmacol 2003;368:262-9.
12. Seok YM, Cho HJ, Cha BY, Woo JT, Kim IK. Honokiol attenu-
ates vascular contraction through the inhibition of the RhoA/
Rho-kinase signalling pathway in rat aortic rings. J Pharm 
Pharmacol 2011;63:1244-51.
13. Bian ZX, Zhang GS, Wong KL, Hu XG, Liu L, Yang Z, et al. 
Herrmann, et al. Honokiol effects in the human prostate
146
PROSTATE INTERNATIONAL
http://dx.doi.org/10.12954/PI.14055
Inhibitory effects of magnolol on distal colon of guinea pig in 
vitro. Biol Pharm Bull 2006;29:790-5.
14. Seok YM, Kim HY, Garmaa O, Cha BY, Woo JT, Kim IK. Effects 
of magnolol on vascular contraction in rat aortic rings. Clin 
Exp Pharmacol Physiol 2012;39:28-36.
15. Teng CM, Yu SM, Chen CC, Huang YL, Huang TF. EDRF-
release and Ca+(+)-channel blockade by magnolol, an anti-
platelet agent isolated from Chinese herb Magnolia officina-
lis, in rat thoracic aorta. Life Sci 1990;47:1153-61.
16. Zhang M, Zang KH, Luo JL, Leung FP, Huang Y, Lin CY, et al. 
Magnolol inhibits colonic motility through down-regulation 
of voltage-sensitive L-type Ca2+ channels of colonic smooth 
muscle cells in rats. Phytomedicine 2013;20:1272-9.
17. Füllhase C, Chapple C, Cornu JN, De Nunzio C, Gratzke C, 
Kaplan SA, et al. Systematic review of combination drug ther-
apy for non-neurogenic male lower urinary tract symptoms. 
Eur Urol 2013;64:228-43.
18. Fan S, Li X, Lin J, Chen S, Shan J, Qi G. Honokiol inhibits tu-
mor necrosis factor-α-stimulated rat aortic smooth muscle 
cell proliferation via caspase- and mitochondrial-dependent 
apoptosis. Inflammation 2014;37:17-26.
19. Hahm ER, Arlotti JA, Marynowski SW, Singh SV. Honokiol, a 
constituent of oriental medicinal herb magnolia officinalis, 
inhibits growth of PC-3 xenografts in vivo in association with 
apoptosis induction. Clin Cancer Res 2008;14:1248-57.
20. Hahm ER, Singh SV. Honokiol causes G0-G1 phase cell cycle 
arrest in human prostate cancer cells in association with sup-
pression of retinoblastoma protein level/phosphorylation 
and inhibition of E2F1 transcriptional activity. Mol Cancer 
Ther 2007;6:2686-95.
21. Lee B, Kim CH, Moon SK. Honokiol causes the p21WAF1-
mediated G(1)-phase arrest of the cell cycle through induc-
ing p38 mitogen activated protein kinase in vascular smooth 
muscle cells. FEBS Lett 2006;580:5177-84.
22. Zhang GS, Wang RJ, Zhang HN, Zhang GP, Luo MS, Luo JD. 
Effects of chronic treatment with honokiol in spontaneously 
hypertensive rats. Biol Pharm Bull 2010;33:427-31.
23. Timms BG, Hofkamp LE. Prostate development and growth in 
benign prostatic hyperplasia. Differentiation 2011;82:173-83.
24. Lee DH, Szczepanski MJ, Lee YJ. Magnolol induces apoptosis 
via inhibiting the EGFR/PI3K/Akt signaling pathway in hu-
man prostate cancer cells. J Cell Biochem 2009;106:1113-22.
25. Karki R, Ho OM, Kim DW. Magnolol attenuates neointima 
formation by inducing cell cycle arrest via inhibition of 
ERK1/2 and NF-kappaB activation in vascular smooth mus-
cle cells. Biochim Biophys Acta 2013;1830:2619-28.
26. Kim HM, Bae SJ, Kim DW, Kim BK, Lee SB, Lee US, et al. Inhibi-
tory role of magnolol on proliferative capacity and matrix me-
talloproteinase-9 expression in TNF-alpha-induced vascular 
smooth muscle cells. Int Immunopharmacol 2007;7:1083-91.
27. Wu CH, Chen CW, Chen HC, Chang WC, Shu MJ, Hung JS. Elu-
cidating the inhibitory mechanisms of magnolol on rat smooth 
muscle cell proliferation. J Pharmacol Sci 2005;99:392-9.
28. Chen JH, Wu CC, Hsiao G, Yen MH. Magnolol induces apop-
tosis in vascular smooth muscle. Naunyn Schmiedebergs 
Arch Pharmacol 2003;368:127-33.
29. Ho JH, Hong CY. Cardiovascular protection of magnolol: cell-
type specificity and dose-related effects. J Biomed Sci 2012; 
19:70.
30. Arora S, Singh S, Piazza GA, Contreras CM, Panyam J, Singh 
AP. Honokiol: a novel natural agent for cancer prevention 
and therapy. Curr Mol Med 2012;12:1244-52.
31. Zheng J, Tang Y, Sun M, Zhao Y, Li Q, Zhou J, et al. Character-
ization, pharmacokinetics, tissue distribution and antitumor 
activity of honokiol submicron lipid emulsions in tumor-
burdened mice. Pharmazie 2013;68:41-6.
32. Liang Y, Cui G, Wang X, Zhang W, An Q, Lin Z, et al. Pharma-
cokinetics of honokiol after intravenous guttae in beagle dogs 
assessed using ultra-performance liquid chromatography-
tandem mass spectrometry. Biomed Chromatogr 2014 Mar 
21 [Epub]. http://dx.doi.org/10.1002/bmc.3179. 
33. Coulson S, Rao A, Beck SL, Steels E, Gramotnev H, Vitetta L. 
A phase II randomised double-blind placebo-controlled clin-
ical trial investigating the efficacy and safety of ProstateEZE 
Max: a herbal medicine preparation for the management of 
symptoms of benign prostatic hypertrophy. Complement 
Ther Med 2013;21:172-9.
34. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD. Random-
ized, double-blind, placebo-controlled trial of saw palmetto in 
men with lower urinary tract symptoms. Urology 2001;58:960-4.
35. Berges RR, Windeler J, Trampisch HJ, Senge T. Randomised, 
placebo-controlled, double-blind clinical trial of beta-
sitosterol in patients with benign prostatic hyperplasia. Beta-
sitosterol Study Group. Lancet 1995;345:1529-32.
36. Safarinejad MR. Urtica dioica for treatment of benign pros-
tatic hyperplasia: a prospective, randomized, double-blind, 
placebo-controlled, crossover study. J Herb Pharmacother 
2005;5:1-11.
37. Lopatkin N, Sivkov A, Walther C, Schlafke S, Medvedev A, 
Avdeichuk J, et al. Long-term efficacy and safety of a combi-
nation of sabal and urtica extract for lower urinary tract symp-
toms: a placebo-controlled, double-blind, multicenter trial. 
World J Urol 2005;23:139-46.
